{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fthink-neuro.simplecast.com%2Fepisodes%2F46-psilocybin-for-major-depressive-disorder-FuVDlpoX","width":444,"version":"1.0","type":"rich","title":"46. Psilocybin for Major Depressive Disorder | Guest Podcast","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/02505544-248a-4a04-b6f7-0cb72662b7b0/8deb1bf5-e00d-4518-8df6-55324c666a90/pni-thinkneuro-e46-jamatripstudy-1x1-thumbnail-r1.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/57a5c57e-4321-4f07-a7ef-5407f474c2b1\" height=\"200\" width=\"100%\" title=\"46. Psilocybin for Major Depressive Disorder | Guest Podcast\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In a study published on August 31, 2023, in the Journal of the American Medical Association, psilocybin showed promise as a treatment for major depressive disorder (MDD). \n\nJAMA Associate Editor Dr. Donald C. Goff, speaks with publication author Dr. Charles L. Raison, from the Usona Institute, about the study, as well as Dr. Rachel Yehuda from Mount Sinai School of Medicine, who wrote an accompanying editorial about the potential benefits of psychedelic therapies. \n\nPacific Neuroscience Institute's director of Treatment & Research In Psychedelics Center, Dr. Keith Heinzerling and PNI director Dr. Daniel Kelly were a co-investigators in this study."}